局部晚期宫颈癌病理性淋巴结的剂量-体积效应
本研究纳入108例接受根治性外照射放疗(EBRT)和图像引导近距离放疗(IGABT)的淋巴结阳性宫颈癌患者,共254枚未切除的病理性淋巴结。中位随访33.5个月,总体淋巴结复发率为9.1%(23/254)。单因素分析显示淋巴结体积(阈值3 cm3,p<.0001)和淋巴结剂量(≥57.5 Gyα/β10,p=.039)与淋巴结控制显著相关;Probit分析显示剂量与体积联合与淋巴结控制概率(NCP)显著相关,且体积越大,额外剂量带来的NCP获益越大。
要点
- 病理性淋巴结体积(阈值3 cm3)和剂量(≥57.5 Gyα/β10)与淋巴结控制显著相关。
- 多因素分析中淋巴结体积(HR=8.2)和剂量(HR=2)为独立影响因素。
- Probit分析显示体积越大,额外剂量对淋巴结控制概率的获益越明显。
核心结论
- 首次证明了病理性淋巴结的剂量-体积效应对淋巴结控制概率(NCP)的影响,体积较大的淋巴结增加剂量后NCP获益更大。
研究设计与样本
- 回顾性识别接受根治性外照射放疗(EBRT)和图像引导近距离放疗(IGABT)的淋巴结阳性宫颈癌患者,共108例患者、254枚未切除的病理性淋巴结。
主要发现
- 诊断时平均淋巴结体积为3.4±5.8 cm3,平均总淋巴结EQD2剂量为55.3±5.6 Gy,96%的患者接受同步化疗。
- 中位随访33.5个月,20例患者(18.5%)在诊断时认为病理性的淋巴结出现复发,总体淋巴结复发率为9.1%(23/254)。
- 单因素分析中,淋巴结体积(阈值3 cm3,p<.0001)和淋巴结剂量(≥57.5 Gyα/β10,p=.039)对淋巴结控制显著,同步加量应用处于显著性边缘(p=.07)。
- Probit分析联合剂量与体积显示与NCP显著相关,且淋巴结体积越大,曲线间差距越大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In cervical cancer patients, dose-volume relationships have been demonstrated for tumor and organs-at-risk, but not for pathologic nodes. The nodal control probability (NCP) according to dose/volume parameters was investigated. MATERIAL AND METHODS: Patients with node-positive cervical cancer treated curatively with external beam radiotherapy (EBRT) and image-guided brachytherapy (IGABT) were identified. Nodal doses during EBRT, IGABT and boost were converted to 2-Gy equivalent (α/β = 10 Gy) and summed. Pathologic nodes were followed individually from diagnosis to relapse. Statistical analyses comprised log-rank tests (univariate analyses), Cox proportional model (factors with p ≤ 0.1 in univariate) and Probit analyses. RESULTS: A total of 108 patients with 254 unresected pathological nodes were identified. The mean nodal volume at diagnosis was 3.4 ± 5.8 cm3. The mean total nodal EQD2 doses were 55.3 ± 5.6 Gy. Concurrent chemotherapy was given in 96%. With a median follow-up of 33.5 months, 20 patients (18.5%) experienced relapse in nodes considered pathologic at diagnosis. Overall nodal recurrence rate was 9.1% (23/254). On univariate analyses, nodal volume (threshold: 3 cm3, p < .0001) and lymph node dose (≥57.5 Gyα/β10, p = .039) were significant for nodal control. The use of simultaneous boost was borderline for significance (p = .07). On multivariate analysis, volume (HR = 8.2, 4.0-16.6, p < .0001) and dose (HR = 2, 1.05-3.9, p = .034) remained independent factors. Probit analysis combining dose and volume showed significant relationships with NCP, with increasing gap between the curves with higher nodal volumes. CONCLUSION: A nodal dose-volume effect on NCP is demonstrated for the first time, with increasing NCP benefit of additional doses to higher-volume nodes.
引用
- Bacorro W, Dumas I, Escande A, et al. Dose-volume effects in pathologic lymph nodes in locally advanced cervical cancer. Gynecol Oncol. 2018. PMID: 29325690. doi:10.1016/j.ygyno.2017.12.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。